Christof von Kalle, MD
Title
Program Leader for Molecular and Gene Therapy
Appointment
Associate Professor of Pediatrics
Email
christof.kalle@cchmc.org
Phone
513-636-1333
Fax
513-636-1330
Credentials
PhD: 1991
MD: Cologne University Medical School, 1981-1987
Position History
2004-present Tenured Associate Professor of Internal Medicine, University of Freiburg, Germany
2002-present Program Leader "Gene and Molecular Therapy" Cincinnati Children's Hospital Medical Center, Experimental Hematology, USA (Prof. Dr. David Williams)
2001 Finalist to Professorship Department for Cell Techniques and Applied Stem Cell Biology, University of Leipzig, Germany
2000-present Group Leader, Section of Hematopoiesis and Gene Transfer, Institute for Molecular Medicine, Freiburg University, Germany
1996-present Senior Clinical Investigator, Gene Therapy Program, and Senior Medical Staff Fellow, Department of Internal Medicine, Freiburg University Medical School, Germany
1995-1996 Clinical Investigator and Senior Resident, Department of Internal Medicine, University of Cologne Medical School, Germany
1992-1994 Associate in Clinical Research, Program of Transplantation Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
1989-1991 Post-doctoral Research Fellow and Clinical Junior Resident, Department of Internal Medicine, University of Cologne Medical School, Germany
1988 Subinternship, Albert Einstein Medical School, New York, USA, Sloan Kettering Cancer Center and Cornell University Medical Center, New York, USA
Awards and Honors
- 2004 Elected, American Society of Clinical Investigation (ASCI)
- 2003 Young Investigators Award, American Society of Gene Therapy
- 2003 Excellence in Research Award (K. Schwarzwaelder), American Society of Gene Therapy
- 2001 Travel Award (Zickler, P), American Society of Hematology
- 2001 Best Presentation Award, (Glimm, H), German Society of Hematology/Oncology
- 2001 Travel Award (Glimm, H), American Society of Hematology
- 2001 Best Presentation Award, (Glimm, H), German Society of Hematology/Oncology
- 2000 Travel Award (Zickler, P), American Society of Hematology
- 2000 Travel Award (Schmidt, M), American Society of Hematology
- 2000 Travel Award (Schmidt, M), American Society of Gene Therapy
- 1999 Travel Award (Schmidt, M), American Society of Hematology
- 1999 van Bekkum Award, European Group for Blood and Marrow Transplantation (EBMT)
- 1998 Best Presentation Award, German Society of Hematology/Oncology
- 1992-1994 Research Fellowship, German Research Foundation (DFG)
- 1982-1987 Scholarship, German Study Foundation (top 1% of graduates)
Research Grants and Contracts
"Vector Insertion and Mutagenesis in Human Hematopoiesis." R01 Application to HP (Hematopoiesis) Study Section NHLB, Principal Investigator, 04/2004
"Molecular Detection of Stem Cell Plasticity, "German Research Foundation, Principal Investigator, 01/2003-06/2005
Publications, Most Recent
Connect to Christof von Kalle's publications on PubMed
Schmidt M, Hacein-Bey-Abina S, Wissler M, Carlier F, Lim A, Prinz C, Glimm H, Andre-Schmutz I, Hue C, Garrigue A, Le Deist F, Lagresle C, Fischer A, Cavazzana-Calvo M, von Kalle C. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial.Blood. 2005 Apr 1;105(7):2699-706.
Laukkanen MO, Kuramoto K, Calmels B, Takatoku M, von Kalle C, Donahue RE, Dunbar CE. Low dose total body irradiation causes clonal fluctuation of primate hematopoietic stem and progenitor cells.Blood. 2005 Feb 1;105(3):1010-5.
Glimm H, Schmidt M, Fischer M, Klingenberg S, Lange W, Waller CF, Eaves CJ, von Kalle C. Evidence of similar effects of short-term culture on the initial repopulating activity of mobilized peripheral blood transplants assessed in NOD/SCID-beta2microglobulin(null) mice and in autografted patients.Exp Hematol. 2005 Jan;33(1):20-5.
Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, Von Kalle C, Barington T, Jakobsen MA, Christensen HO, Al Ghonaium A, White HN, Smith JL, Levinsky RJ, Ali RR, Kinnon C, Thrasher AJ. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.Lancet. 2004 Dec 18-31;364(9452):2181-7.
Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, Sellers S, Holt IE, Eckfeldt CE, Sharma Y, Schmidt M, von Kalle C, Persons DA, Billings EM, Verfaillie CM, Nienhuis AW, Wolfsberg TG, Dunbar CE, Calmels B. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells.PLoS Biol. 2004 Dec;2(12):e423.
von Kalle C, Fehse B, Layh-Schmitt G, Schmidt M, Kelly P, Baum C. Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable.Semin Hematol. 2004 Oct;41(4):303-18. Review.
Milsom MD, Duxbury R, Gagen D, Humphries RK, Schmidt M, von Kalle C, Fairbairn LJ. Overexpression of HOXB4 confers a myelo-erythroid differentiation delay in vitro.Leukemia. 2005 Jan;19(1):148-53.
von Kalle C, Baum C, Williams DA. Lenti in red: progress in gene therapy for human hemoglobinopathies.J Clin Invest. 2004 Oct;114(7):889-91.
Fischer A, Abina SH, Thrasher A, von Kalle C, Cavazzana-Calvo M. LMO2 and gene therapy for severe combined immunodeficiency.N Engl J Med. 2004 Jun 10;350(24):2526-7; author reply 2526-7.
Kuramoto K, Follman D, Hematti P, Sellers S, Laukkanen MO, Seggewiss R, Metzger ME, Krouse A, Donahue RE, von Kalle C, Dunbar CE. The impact of low-dose busulfan on clonal dynamics in nonhuman primates.Blood. 2004 Sep 1;104(5):1273-80.
Kiem HP, Sellers S, Thomasson B, Morris JC, Tisdale JF, Horn PA, Hematti P, Adler R, Kuramoto K, Calmels B, Bonifacino A, Hu J, von Kalle C, Schmidt M, Sorrentino B, Nienhuis A, Blau CA, Andrews RG, Donahue RE, Dunbar CE. Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia.Mol Ther. 2004 Mar;9(3):389-95.
Baum C, von Kalle C, Staal FJ, Li Z, Fehse B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker G, Williams DA. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences.Mol Ther. 2004 Jan;9(1):5-13. Review.
Neff T, Horn PA, Peterson LJ, Thomasson BM, Thompson J, Williams DA, Schmidt M, Georges GE, von Kalle C, Kiem HP. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model.J Clin Invest. 2003 Nov;112(10):1581-8.
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.Science. 2003 Oct 17;302(5644):415-9. Erratum in: Science. 2003 Oct 24;302(5645):568.
Baum C, von Kalle C. Gene therapy targeting hematopoietic cells: better not leave it to chance.Acta Haematol. 2003;110(2-3):107-9. Review.
Gao C, Kang EM, Kuramoto K, Agricola BA, Metzger M, von Kalle C, Donahue RE, Tisdale, JF. Retrovirally transduced muscle derived cells contribute to hematopoiesis at very low levels in the non-human primate model.Molecular Therapy, 2003 Dec;8(6):974-80.
Schmidt M, Glimm H, Wissler M, Hoffmann G, Olsson K, Sellers S, Carbonaro D, Tisdale JF, Leurs C, Hanenberg H, Dunbar CE, Kiem HP, Karlsson S, Kohn DB, Williams D, Von Kalle C. Efficient characterization of retro-, lenti-, and foamyvector-transduced cell populations by high-accuracy insertion site sequencing.Ann N Y Acad Sci. 2003 May;996:112-21.
Leurs C, Jansen M, Pollok KE, Heinkelein M, Schmidt M, Wissler M, Lindemann D, Von Kalle C, Rethwilm A, Williams DA, Hanenberg H. Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells.Hum Gene Ther. 2003 Apr 10;14(6):509-19.
Schmidt M, Carbonaro D, Speckmann C, Wissler M, Bohnsack J, Elder M, Aronow B, Nolta JA, Kohn DB and von Kalle C. Clonality Analysis after Retroviral-Mediated Gene Transfer To CD34+ Cells from the Cord Blood of ADA-Deficient SCID Neonates.Nat Med. 2003 Apr;9(4):463-8.
Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA, von Kalle C. Side effects of retroviral gene transfer into hematopoietic stem cells.Blood. 2003 Mar 15;101(6):2099-114.
Woods NB, Muessig A, Schmidt M, Flygare J, Olsson K, Salmon P, Trono D, von Kalle C, Karlsson S. Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis.Blood. 2003 Feb 15;101(4):1284-9.
Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.N Engl J Med. 2003 Jan 16;348(3):255-6.
Presentations, Most Recent
- American Association of Cancer Research (AACR), 2004 Annual Meeting, 03-30-2004.
- American Society of Hematology, Meet the Professor Expert, 2004 Annual Meeting, San Diego, California.
- American College of Medical Genetics (ACMG/SIMD), 2004 Annual Meeting Plenary Session Speaker, Orlando, Florida, 03-07-04
- Tandem BMT Meeting, Session Chair and Concurrent Plenary Session Speaker, Orlando, Florida 02-16-04
- INHERINET Annual Meeting, Barcelona, State-of-the-Art Presenter, 01-09 to 10-04
- Stem Cell Clonality and Genotoxicity Retreat, San Diego, Organizer, Co-Chair and Speaker, 12-10-03
- ICH Meeting 6, Plenary Session Speaker, Osaka, Japan, 11-12-03
- European Society of Gene Therapy Meeting, Plenary Session Speaker, Edinburgh, UK11-15-03
- Falk-Symposium, Freiburg, Germany; 10-20 to 21-03
- Wilsede Meeting; Wilsede, Germany; 04-07-03
- Retrovirus Pathogenesis Meeting, Glasgow, 09-17-03
- ESGLD-Meeting, Prague; 09-20-2003
- German Research Foundation (DFG)-Priority Program Meeting in Dresden; 19.09.03
- SFB 364 Meeting, University of Freiburg; Freiburg; 07-07-2003
- MD Anderson Cancer Center, Houston, Texas 07-04-03
- ASGT-Meeting, Washington; Prize Recipient Session Speaker, 06-04 to 08-03
- Australasian Gene Therapy Society Meeting, Plenary Session Speaker, Brisbane 04-30-03
- Sidney Children's Hospital, Australia, 29.04.03
- Japanese Gene Therapy Meeting, Plenary Session Speaker, Japan 03-10-03
- St. Jude Children's Hospital, Memphis, USA 03-08-03
- Stanford University, California, USA 02-21-2003
- Work in Progress Meeting, University of Freiburg; 02-17-03
- Children's Hospital, University of Pensylvania, 02-12-03
- Inherinet-Meeting in Lund;01- 9-11, 2003
